Advertisement

Mesenchymal Stem Cells for Acute Lung Injury

  • Jae W. LeeEmail author
  • Naveen Gupta
  • Michael A. Matthay
Chapter
  • 558 Downloads
Part of the Stem Cell Biology and Regenerative Medicine book series (STEMCELL)

Abstract

Despite extensive research into the pathogenesis of acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS), mortality remains high, approaching 30% even with lung-protective ventilation and a fluid conservative strategy. Pharmacologic therapies that reduce the severity of lung injury in vivo and in vitro have not yet been translated into effective clinical treatment options. Therefore, innovative therapies are needed. Recent studies have suggested that bone-marrow-derived multipotent mesenchymal stem cells (MSCs) may have therapeutic applications in multiple clinical disorders, including myocardial infarction, diabetes, sepsis, hepatic failure, and acute renal failure. Recently, MSCs have been studied in several in vivo models of lung disease. This review focuses first on describing the existing experimental literature that has tested the use of MSCs in models of ALI/ARDS, and then on describing the potential mechanisms underlying their therapeutic use with an emphasis on secreted paracrine soluble factors.

Keywords

Acute respiratory distress syndrome Mesenchymal stem cells Paracrine soluble factors Pulmonary edema 

References

  1. 1.
    Ware LB, and Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342:1334–1349.PubMedCrossRefGoogle Scholar
  2. 2.
    Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, and Hudson LD. Incidence and outcomes of acute lung injury. N Engl J Med 2005; 353:1685–1693.PubMedCrossRefGoogle Scholar
  3. 3.
    Matthay MA, and Zimmerman GA. Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management. Am J Respir Cell Mol Biol 2005; 33:319–327.PubMedCrossRefGoogle Scholar
  4. 4.
    The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342:1301–1308.CrossRefGoogle Scholar
  5. 5.
    Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, Connors AF Jr, Hite RD, and Harabin AL. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354:2564–2575.PubMedCrossRefGoogle Scholar
  6. 6.
    Erickson SE, Martin GS, Davis JL, Matthay MA, and Eisner MD. Recent trends in acute lung injury mortality: 1996–2005. Crit Care Med 2009; 37:1574–1579.PubMedCrossRefGoogle Scholar
  7. 7.
    Li TS, Hayashi M, Ito H, Furutani A, Murata T, Matsuzaki M, and Hamano K. Regeneration of infarcted myocardium by intramyocardial implantation of ex vivo transforming growth factor-beta-preprogrammed bone marrow stem cells. Circulation 2005; 111:2438–2445.PubMedCrossRefGoogle Scholar
  8. 8.
    Miyahara Y, Nagaya N, Kataoka M, Yanagawa B, Tanaka K, Hao H, Ishino K, Ishida H, Shimizu T, Kangawa K et al. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med 2006; 12:459–465.PubMedCrossRefGoogle Scholar
  9. 9.
    Iso Y, Spees JL, Serrano C, Bakondi B, Pochampally R, Song YH, Sobel BE, Delafontaine P, and Prockop DJ. Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochem Biophys Res Commun 2007; 354:700–706.PubMedCrossRefGoogle Scholar
  10. 10.
    Lee RH, Seo MJ, Reger RL, Spees JL, Pulin AA, Olson SD, and Prockop DJ. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA 2006; 103:17438–17443.PubMedCrossRefGoogle Scholar
  11. 11.
    Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH, Brown JM et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15:42–49.PubMedCrossRefGoogle Scholar
  12. 12.
    Parekkadan B, van Poll D, Suganuma K, Carter EA, Berthiaume F, Tilles AW, and Yarmush ML. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS One 2007; 2:e941.PubMedCrossRefGoogle Scholar
  13. 13.
    Togel F, Hu Z, Weiss K, Isaac J, Lange C, and Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005; 289:F31–F42.PubMedCrossRefGoogle Scholar
  14. 14.
    Prockop DJ. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther 2009; 17:939–946.PubMedCrossRefGoogle Scholar
  15. 15.
    Friedenstein AJ, Petrakova KV, Kurolesova AI, and Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968; 6:230–247.PubMedCrossRefGoogle Scholar
  16. 16.
    da Silva Meirelles L, Chagastelles PC, and Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006; 119:2204–2213.PubMedCrossRefGoogle Scholar
  17. 17.
    Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, and Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8:315–317.PubMedCrossRefGoogle Scholar
  18. 18.
    Patel SA, Sherman L, Munoz J, and Rameshwar P. Immunological properties of mesenchymal stem cells and clinical implications. Arch Immunol Ther Exp (Warsz) 2008; 56:1–8.CrossRefGoogle Scholar
  19. 19.
    Chan JL, Tang KC, Patel AP, Bonilla LM, Pierobon N, Ponzio NM, and Rameshwar P. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 2006; 107:4817–4824.PubMedCrossRefGoogle Scholar
  20. 20.
    Stagg J, Pommey S, Eliopoulos N, and Galipeau J. Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood 2006; 107:2570–2577.PubMedCrossRefGoogle Scholar
  21. 21.
    Stagg J. Immune regulation by mesenchymal stem cells: two sides to the coin. Tissue Antigens 2007; 69:1–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, and Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006; 108:2114–2120.PubMedCrossRefGoogle Scholar
  23. 23.
    Weiss DJ, Kolls JK, Ortiz LA, Panoskaltsis-Mortari A, and Prockop DJ. Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc 2008; 5:637–667.PubMedCrossRefGoogle Scholar
  24. 24.
    Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, and Phinney DG. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003; 100:8407–8411.PubMedCrossRefGoogle Scholar
  25. 25.
    Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, and Phinney DG. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA 2007; 104:11002–11007.PubMedCrossRefGoogle Scholar
  26. 26.
    Yamada M, Kubo H, Kobayashi S, Ishizawa K, Numasaki M, Ueda S, Suzuki T, and Sasaki H. Bone marrow-derived progenitor cells are important for lung repair after lipopolysaccharide-induced lung injury. J Immunol 2004; 172:1266–1272.PubMedGoogle Scholar
  27. 27.
    Rojas M, Xu J, Woods CR, Mora AL, Spears W, Roman J, and Brigham KL. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 2005; 33:145–152.PubMedCrossRefGoogle Scholar
  28. 28.
    Xu J, Woods CR, Mora AL, Joodi R, Brigham KL, Iyer S, and Rojas M. Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. Am J Physiol Lung Cell Mol Physiol 2007; 293:L131–L141.PubMedCrossRefGoogle Scholar
  29. 29.
    Gupta N, Su X, Popov B, Lee JW, Serikov V, and Matthay MA. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007; 179:1855–1863.PubMedGoogle Scholar
  30. 30.
    Mei SH, McCarter SD, Deng Y, Parker CH, Liles WC, and Stewart DJ. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med 2007; 4:e269.PubMedCrossRefGoogle Scholar
  31. 31.
    Zhen G, Liu H, Gu N, Zhang H, Xu Y, and Zhang Z. Mesenchymal stem cells transplantation protects against rat pulmonary emphysema. Front Biosci 2008; 13:3415–3422.PubMedCrossRefGoogle Scholar
  32. 32.
    Xu J, Qu J, Cao L, Sai Y, Chen C, He L, and Yu L. Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. J Pathol 2008; 214:472–481.PubMedCrossRefGoogle Scholar
  33. 33.
    Su X, Looney MR, Gupta N, and Matthay MA. Receptor for advanced glycation end-products (RAGE) is an indicator of direct lung injury in models of experimental lung injury. Am J Physiol Lung Cell Mol Physiol 2009; 297:L1–L5.PubMedCrossRefGoogle Scholar
  34. 34.
    Frank JA, Briot R, Lee JW, Ishizaka A, Uchida T, and Matthay MA. Physiological and biochemical markers of alveolar epithelial barrier dysfunction in perfused human lungs. Am J Physiol Lung Cell Mol Physiol 2007; 293:L52–L59.PubMedCrossRefGoogle Scholar
  35. 35.
    Lee JW, Gupta N, Fang X, Frank JA, and Matthay MA. Human mesenchymal stem cells reduce endotoxin induced acute lung injury in the ex vivo perfused human lung. Am J Respir Cell Mol Biol 2008; 177:A598.Google Scholar
  36. 36.
    Neyrinck AP, Lee JW, Fang X, Gupta N, and Matthay MA. Angiopoietin-1 reverses protein permeability in an injured model of cultured human alveolar epithelial type II cells. FASEB J 2008; 22(932):936.Google Scholar
  37. 37.
    Krause DS, Theise ND, Collector MI, Henegariu O, Hwang S, Gardner R, Neutzel S, and Sharkis SJ. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 2001; 105:369–377.PubMedCrossRefGoogle Scholar
  38. 38.
    Kotton DN, Ma BY, Cardoso WV, Sanderson EA, Summer RS, Williams MC, and Fine A. Bone marrow-derived cells as progenitors of lung alveolar epithelium. Development 2001; 128:5181–5188.PubMedGoogle Scholar
  39. 39.
    Wang G, Bunnell BA, Painter RG, Quiniones BC, Tom S, Lanson NA Jr, Spees JL, Bertucci D, Peister A, Weiss DJ et al. Adult stem cells from bone marrow stroma differentiate into airway epithelial cells: potential therapy for cystic fibrosis. Proc Natl Acad Sci USA 2005; 102:186–191.PubMedCrossRefGoogle Scholar
  40. 40.
    Spees JL, Pociask DA, Sullivan DE, Whitney MJ, Lasky JA, Prockop DJ, and Brody AR. Engraftment of bone marrow progenitor cells in a rat model of asbestos-induced pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176:385–394.PubMedCrossRefGoogle Scholar
  41. 41.
    Hung SC, Pochampally RR, Hsu SC, Sanchez C, Chen SC, Spees J, and Prockop DJ. Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. PLoS One 2007; 2:e416.PubMedCrossRefGoogle Scholar
  42. 42.
    Wagers AJ, Sherwood RI, Christensen JL, and Weissman IL. Little evidence for developmental plasticity of adult hematopoietic stem cells. Science 2002; 297:2256–2259.PubMedCrossRefGoogle Scholar
  43. 43.
    Kotton DN, Fabian AJ, and Mulligan RC. Failure of bone marrow to reconstitute lung epithelium. Am J Respir Cell Mol Biol 2005; 33:328–334.PubMedCrossRefGoogle Scholar
  44. 44.
    Loi R, Beckett T, Goncz KK, Suratt BT, and Weiss DJ. Limited restoration of cystic fibrosis lung epithelium in vivo with adult bone marrow-derived cells. Am J Respir Crit Care Med 2006; 173:171–179.PubMedCrossRefGoogle Scholar
  45. 45.
    Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, and Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31:890–896.PubMedCrossRefGoogle Scholar
  46. 46.
    Aggarwal S, and Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105:1815–1822.PubMedCrossRefGoogle Scholar
  47. 47.
    Glennie S, Soeiro I, Dyson PJ, Lam EW, and Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105:2821–2827.PubMedCrossRefGoogle Scholar
  48. 48.
    Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, and Gianni AM. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99:3838–3843.PubMedCrossRefGoogle Scholar
  49. 49.
    Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW, Deans RJ, and McIntosh KR. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 2005; 12:47–57.PubMedCrossRefGoogle Scholar
  50. 50.
    Rasmusson I, Ringden O, Sundberg B, and Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76:1208–1213.PubMedCrossRefGoogle Scholar
  51. 51.
    Chen L, Tredget EE, Wu PY, and Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 2008; 3:e1886.PubMedCrossRefGoogle Scholar
  52. 52.
    Sueblinvong V, Loi R, Eisenhauer PL, Bernstein IM, Suratt BT, Spees JL, and Weiss DJ. Derivation of lung epithelium from human cord blood-derived mesenchymal stem cells. Am J Respir Crit Care Med 2008; 177:701–711.PubMedCrossRefGoogle Scholar
  53. 53.
    Wong AP, Dutly AE, Sacher A, Lee H, Hwang DM, Liu M, Keshavjee S, Hu J, and Waddell TK. Targeted cell replacement with bone marrow cells for airway epithelial regeneration. Am J Physiol Lung Cell Mol Physiol 2007; 293:L740–L752.PubMedCrossRefGoogle Scholar
  54. 54.
    Wong AP, Keating A, Lu WY, Duchesneau P, Wang X, Sacher A, Hu J, and Waddell TK. Identification of a bone marrow-derived epithelial-like population capable of repopulating injured mouse airway epithelium. J Clin Invest 2009; 119:336–348.PubMedGoogle Scholar
  55. 55.
    Popov BV, Serikov VB, Petrov NS, Izusova TV, Gupta N, and Matthay MA. Lung epithelial cells induce endodermal differentiation in mouse mesenchymal bone marrow stem cells by paracrine mechanism. Tissue Eng 2007; 13:2441–2450.PubMedCrossRefGoogle Scholar
  56. 56.
    Serikov VB, Popov B, Mikhailov VM, Gupta N, and Matthay MA. Evidence of temporary airway epithelial repopulation and rare clonal formation by BM-derived cells following naphthalene injury in mice. Anat Rec (Hoboken) 2007; 290:1033–1045.CrossRefGoogle Scholar
  57. 57.
    Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, Galun E, and Rachmilewitz J. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005; 105:2214–2219.PubMedCrossRefGoogle Scholar
  58. 58.
    Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi GL, Pistoia V et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107:367–372.PubMedCrossRefGoogle Scholar
  59. 59.
    Geiser T, Atabai K, Jarreau PH, Ware LB, Pugin J, and Matthay MA. Pulmonary edema fluid from patients with acute lung injury augments in vitro alveolar epithelial repair by an IL-1beta-dependent mechanism. Am J Respir Crit Care Med 2001; 163:1384–1388.PubMedGoogle Scholar
  60. 60.
    Rasmusson I, Le Blanc K, Sundberg B, and Ringden O. Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol 2007; 65:336–343.PubMedCrossRefGoogle Scholar
  61. 61.
    Raffaghello L, Bianchi G, Bertolotto M, Montecucco F, Busca A, Dallegri F, Ottonello L, and Pistoia V. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells 2008; 26:151–162.PubMedCrossRefGoogle Scholar
  62. 62.
    Gupta N, and Mattay MA. Mesenchymal stem cells enhance bacterial clearance and reduce mortality and lung injury from E. coli pneumonia. Am J Respir Crit Care Med 2009; 179:A5111.Google Scholar
  63. 63.
    Aguilar S, Nye E, Chan J, Loebinger M, Spencer-Dene B, Fisk N, Stamp G, Bonnet D, and Janes SM. Murine but not human mesenchymal stem cells generate osteosarcoma-like lesions in the lung. Stem Cells 2007; 25:1586–1594.PubMedCrossRefGoogle Scholar
  64. 64.
    Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S, Xia L, Zhou N, Riddle M, Schroeder TM et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007; 25:371–379.PubMedCrossRefGoogle Scholar
  65. 65.
    Izadpanah R, Kaushal D, Kriedt C, Tsien F, Patel B, Dufour J, and Bunnell BA. Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res 2008; 68:4229–4238.PubMedCrossRefGoogle Scholar
  66. 66.
    Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, and Weinberg RA. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449:557–563.PubMedCrossRefGoogle Scholar
  67. 67.
    Corcoran KE, Trzaska KA, Fernandes H, Bryan M, Taborga M, Srinivas V, Packman K, Patel PS, and Rameshwar P. Mesenchymal stem cells in early entry of breast cancer into bone marrow. PLoS One 2008; 3:e2563.PubMedCrossRefGoogle Scholar
  68. 68.
    Otsu K, Das S, Houser SD, Quadri SK, Bhattacharya S, and Bhattacharya J. Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Blood 2009; 113:4197–4205.PubMedCrossRefGoogle Scholar
  69. 69.
    Matthay MA, and Wiener-Kronish JP. Intact epithelial barrier function is critical for the resolution of alveolar edema in humans. Am Rev Respir Dis 1990; 142:1250–1257.PubMedGoogle Scholar
  70. 70.
    Ware LB, and Matthay MA. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 163:1376–1383.PubMedGoogle Scholar
  71. 71.
    Matthay MA, Folkesson HG, and Clerici C. Lung epithelial fluid transport and the resolution of pulmonary edema. Physiol Rev 2002; 82:569–600.PubMedGoogle Scholar
  72. 72.
    Folkesson HG, and Matthay MA. Alveolar epithelial ion and fluid transport: recent progress. Am J Respir Cell Mol Biol 2006; 35:10–19.PubMedCrossRefGoogle Scholar
  73. 73.
    Matalon S, and O’Brodovich H. Sodium channels in alveolar epithelial cells: molecular characterization, biophysical properties, and physiological significance. Annu Rev Physiol 1999; 61:627–661.PubMedCrossRefGoogle Scholar
  74. 74.
    Eaton DC, Chen J, Ramosevac S, Matalon S, and Jain L. Regulation of Na+ channels in lung alveolar type II epithelial cells. Proc Am Thorac Soc 2004; 1:10–16.PubMedCrossRefGoogle Scholar
  75. 75.
    Mutlu GM, and Sznajder JI. Mechanisms of pulmonary edema clearance. Am J Physiol Lung Cell Mol Physiol 2005; 289:L685–L695.PubMedCrossRefGoogle Scholar
  76. 76.
    Matalon S, Lazrak A, Jain L, and Eaton DC. Invited review: biophysical properties of sodium channels in lung alveolar epithelial cells. J Appl Physiol 2002; 93:1852–1859.PubMedGoogle Scholar
  77. 77.
    Fang X, Song Y, Hirsch J, Galietta LJ, Pedemonte N, Zemans RL, Dolganov G, Verkman AS, and Matthay MA. Contribution of CFTR to apical-basolateral fluid transport in cultured human alveolar epithelial type II cells. Am J Physiol Lung Cell Mol Physiol 2006; 290:L242–L249.PubMedCrossRefGoogle Scholar
  78. 78.
    Brochiero E, Dagenais A, Prive A, Berthiaume Y, and Grygorczyk R. Evidence of a functional CFTR Cl(–) channel in adult alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 2004; 287:L382–L392.PubMedCrossRefGoogle Scholar
  79. 79.
    Mutlu GM, Adir Y, Jameel M, Akhmedov AT, Welch L, Dumasius V, Meng FJ, Zabner J, Koenig C, Lewis ER et al. Interdependency of beta-adrenergic receptors and CFTR in regulation of alveolar active Na+ transport. Circ Res 2005; 96:999–1005.PubMedCrossRefGoogle Scholar
  80. 80.
    Pugin J, Verghese G, Widmer MC, and Matthay MA. The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome. Crit Care Med 1999; 27:304–312.PubMedCrossRefGoogle Scholar
  81. 81.
    Olman MA, White KE, Ware LB, Simmons WL, Benveniste EN, Zhu S, Pugin J, and Matthay MA. Pulmonary edema fluid from patients with early lung injury stimulates fibroblast proliferation through IL-1 beta-induced IL-6 expression. J Immunol 2004; 172:2668–2677.PubMedGoogle Scholar
  82. 82.
    Lee JW, Fang X, Dolganov G, Fremont RD, Bastarache JA, Ware LB, and Matthay MA. Acute lung injury edema fluid decreases net fluid transport across human alveolar epithelial type II cells. J Biol Chem 2007; 282:24109–24119.PubMedCrossRefGoogle Scholar
  83. 83.
    Dagenais A, Frechette R, Yamagata Y, Yamagata T, Carmel JF, Clermont ME, Brochiero E, Masse C, and Berthiaume Y. Downregulation of ENaC activity and expression by TNF-alpha in alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 2004; 286: L301–L311.PubMedCrossRefGoogle Scholar
  84. 84.
    Roux J, Kawakatsu H, Gartland B, Pespeni M, Sheppard D, Matthay MA, Canessa CM, and Pittet JF. Interleukin-1beta decreases expression of the epithelial sodium channel alpha-subunit in alveolar epithelial cells via a p38 MAPK-dependent signaling pathway. J Biol Chem 2005; 280:18579–18589.PubMedCrossRefGoogle Scholar
  85. 85.
    Frank J, Roux J, Kawakatsu H, Su G, Dagenais A, Berthiaume Y, Howard M, Canessa CM, Fang X, Sheppard D et al. Transforming growth factor-beta1 decreases expression of the epithelial sodium channel alphaENaC and alveolar epithelial vectorial sodium and fluid transport via an ERK1/2-dependent mechanism. J Biol Chem 2003; 278:43939–43950.PubMedCrossRefGoogle Scholar
  86. 86.
    Pruliere-Escabasse V, Fanen P, Dazy AC, Lechapt-Zalcman E, Rideau D, Edelman A, Escudier E, and Coste A. TGF-beta 1 downregulates CFTR expression and function in nasal polyps of non-CF patients. Am J Physiol Lung Cell Mol Physiol 2005; 288:L77–L83.PubMedCrossRefGoogle Scholar
  87. 87.
    Nemzek JA, Ebong SJ, Kim J, Bolgos GL, and Remick DG. Keratinocyte growth factor pretreatment is associated with decreased macrophage inflammatory protein-2alpha concentrations and reduced neutrophil recruitment in acid aspiration lung injury. Shock 2002; 18:501–506.PubMedCrossRefGoogle Scholar
  88. 88.
    Yano T, Deterding RR, Simonet WS, Shannon JM, and Mason RJ. Keratinocyte growth factor reduces lung damage due to acid instillation in rats. Am J Respir Cell Mol Biol 1996; 15:433–442.PubMedGoogle Scholar
  89. 89.
    Sugahara K, Iyama K, Kuroda MJ, and Sano K. Double intratracheal instillation of keratinocyte growth factor prevents bleomycin-induced lung fibrosis in rats. J Pathol 1998; 186:90–98.PubMedCrossRefGoogle Scholar
  90. 90.
    Yi ES, Salgado M, Williams S, Kim SJ, Masliah E, Yin S, and Ulich TR. Keratinocyte growth factor decreases pulmonary edema, transforming growth factor-beta and platelet-derived growth factor-BB expression, and alveolar type II cell loss in bleomycin-induced lung injury. Inflammation 1998; 22:315–325.PubMedCrossRefGoogle Scholar
  91. 91.
    Barazzone C, Donati YR, Rochat AF, Vesin C, Kan CD, Pache JC, and Piguet PF. Keratinocyte growth factor protects alveolar epithelium and endothelium from oxygen-induced injury in mice. Am J Pathol 1999; 154:1479–1487.PubMedCrossRefGoogle Scholar
  92. 92.
    Panos RJ, Bak PM, Simonet WS, Rubin JS, and Smith LJ. Intratracheal instillation of keratinocyte growth factor decreases hyperoxia-induced mortality in rats. J Clin Invest 1995; 96:2026–2033.PubMedCrossRefGoogle Scholar
  93. 93.
    Viget NB, Guery BP, Ader F, Neviere R, Alfandari S, Creuzy C, Roussel-Delvallez M, Foucher C, Mason CM, Beaucaire G et al. Keratinocyte growth factor protects against Pseudomonas aeruginosa-induced lung injury. Am J Physiol Lung Cell Mol Physiol 2000; 279:L1199–L1209.PubMedGoogle Scholar
  94. 94.
    Wang Y, Folkesson HG, Jayr C, Ware LB, and Matthay MA. Alveolar epithelial fluid transport can be simultaneously upregulated by both KGF and beta-agonist therapy. J Appl Physiol 1999; 87:1852–1860.PubMedGoogle Scholar
  95. 95.
    Guery BP, Mason CM, Dobard EP, Beaucaire G, Summer WR, and Nelson S. Keratinocyte growth factor increases transalveolar sodium reabsorption in normal and injured rat lungs. Am J Respir Crit Care Med 1997; 155:1777–1784.PubMedGoogle Scholar
  96. 96.
    Yano T, Mason RJ, Pan T, Deterding RR, Nielsen LD, and Shannon JM. KGF regulates pulmonary epithelial proliferation and surfactant protein gene expression in adult rat lung. Am J Physiol Lung Cell Mol Physiol 2000; 279:L1146–L1158.PubMedGoogle Scholar
  97. 97.
    Ware LB, and Matthay MA. Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair. Am J Physiol Lung Cell Mol Physiol 2002; 282:L924–L940.PubMedGoogle Scholar
  98. 98.
    Dada LA, and Sznajder JI. Mechanisms of pulmonary edema clearance during acute hypoxemic respiratory failure: role of the Na,K-ATPase. Crit Care Med 2003; 31: S248–S252.PubMedCrossRefGoogle Scholar
  99. 99.
    Planes C, Blot-Chabaud M, Matthay MA, Couette S, Uchida T, and Clerici C. Hypoxia and beta 2-agonists regulate cell surface expression of the epithelial sodium channel in native alveolar epithelial cells. J Biol Chem 2002; 277:47318–47324.PubMedCrossRefGoogle Scholar
  100. 100.
    Kwak HJ, So JN, Lee SJ, Kim I, and Koh GY. Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett 1999; 448:249–253.PubMedCrossRefGoogle Scholar
  101. 101.
    Gamble JR, Drew J, Trezise L, Underwood A, Parsons M, Kasminkas L, Rudge J, Yancopoulos G, and Vadas MA. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res 2000; 87:603–607.PubMedCrossRefGoogle Scholar
  102. 102.
    Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, and McDonald DM. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999; 286:2511–2514.PubMedCrossRefGoogle Scholar
  103. 103.
    Kim I, Moon SO, Park SK, Chae SW, and Koh GY. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res 2001; 89:477–479.PubMedCrossRefGoogle Scholar
  104. 104.
    Pizurki L, Zhou Z, Glynos K, Roussos C, and Papapetropoulos A. Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production. Br J Pharmacol 2003; 139:329–336.PubMedCrossRefGoogle Scholar
  105. 105.
    McCarter SD, Mei SH, Lai PF, Zhang QW, Parker CH, Suen RS, Hood RD, Zhao YD, Deng Y, Han RN et al. Cell-based angiopoietin-1 gene therapy for acute lung injury. Am J Respir Crit Care Med 2007; 175:1014–1026.PubMedCrossRefGoogle Scholar
  106. 106.
    Mason CM, Guery BP, Summer WR, and Nelson S. Keratinocyte growth factor attenuates lung leak induced by alpha-naphthylthiourea in rats. Crit Care Med 1996; 24:925–931.PubMedCrossRefGoogle Scholar
  107. 107.
    Welsh DA, Summer WR, Dobard EP, Nelson S, and Mason CM. Keratinocyte growth factor prevents ventilator-induced lung injury in an ex vivo rat model. Am J Respir Crit Care Med 2000; 162:1081–1086.PubMedGoogle Scholar
  108. 108.
    Murakami M, Nguyen LT, Zhang ZW, Moodie KL, Carmeliet P, Stan RV, and Simons M. The FGF system has a key role in regulating vascular integrity. J Clin Invest 2008; 118:3355–3366.PubMedCrossRefGoogle Scholar
  109. 109.
    Birukova AA, Alekseeva E, Mikaelyan A, and Birukov KG. HGF attenuates thrombin-induced endothelial permeability by Tiam1-mediated activation of the Rac pathway and by Tiam1/Rac-dependent inhibition of the Rho pathway. FASEB J 2007; 21:2776–2786.PubMedCrossRefGoogle Scholar
  110. 110.
    Singleton PA, Salgia R, Moreno-Vinasco L, Moitra J, Sammani S, Mirzapoiazova T, and Garcia JG. CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. J Biol Chem 2007; 282:30643–30657.PubMedCrossRefGoogle Scholar
  111. 111.
    Lam CF, Liu YC, Hsu JK, Yeh PA, Su TY, Huang CC, Lin MW, Wu PC, Chang PJ, and Tsai YC. Autologous transplantation of endothelial progenitor cells attenuates acute lung injury in rabbits. Anesthesiology 2008; 108:392–401.PubMedCrossRefGoogle Scholar
  112. 112.
    Burnham EL, Taylor WR, Quyyumi AA, Rojas M, Brigham KL, and Moss M. Increased circulating endothelial progenitor cells are associated with survival in acute lung injury. Am J Respir Crit Care Med 2005; 172:854–860.PubMedCrossRefGoogle Scholar
  113. 113.
    Yamada M, Kubo H, Ishizawa K, Kobayashi S, Shinkawa M, and Sasaki H. Increased circulating endothelial progenitor cells in patients with bacterial pneumonia: evidence that bone marrow derived cells contribute to lung repair. Thorax 2005; 60:410–413.PubMedCrossRefGoogle Scholar
  114. 114.
    Lee RH, Seo MJ, Pulin AA, Gregory CA, Ylostalo J, and Prockop DJ. The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood 2009; 113:816–826.PubMedCrossRefGoogle Scholar
  115. 115.
    Koga H, Muneta T, Nagase T, Nimura A, Ju YJ, Mochizuki T, and Sekiya I. Comparison of mesenchymal tissues-derived stem cells for in vivo chondrogenesis: suitable conditions for cell therapy of cartilage defects in rabbit. Cell Tissue Res 2008; 333:207–215.PubMedCrossRefGoogle Scholar
  116. 116.
    Serikov V, Hounshell C, Larkin SK, Green W, Ikeda H, Walters MC, and Kuypers FA. Human Term Placenta as a source of Hematopoietic Cells. Exp Biol Med (Maywood) 2009; 234:813–823.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Jae W. Lee
    • 1
    Email author
  • Naveen Gupta
    • 2
  • Michael A. Matthay
    • 1
    • 2
  1. 1.Departments of Medicine and AnesthesiologyUniversity of CaliforniaSan FranciscoUSA
  2. 2.Cardiovascular Research InstituteUniversity of CaliforniaSan FranciscoUSA

Personalised recommendations